3 Top Undervalued Asian Small Caps With Recent Insider Buying

In recent weeks, Asian markets have experienced notable volatility, influenced by fluctuating oil prices and geopolitical tensions in the Middle East. Despite these challenges, opportunities remain for investors seeking value in small-cap stocks, particularly those with strong fundamentals and insider buying activity.

Top 10 Undervalued Small Caps With Insider Buying In Asia

Name	PE	PS	Discount to Fair Value	Value Rating
Centurion	11.3x	3.9x	36.08%	★★★★★★
Security Bank	4.4x	0.9x	23.55%	★★★★★★
East West Banking	2.9x	0.7x	34.39%	★★★★★☆
Paragon Care	NA	0.1x	41.50%	★★★★★☆
Natural Food International Holding	11.4x	1.2x	7.74%	★★★★☆☆
Nam Cheong	4.2x	2.3x	-23.23%	★★★★☆☆
GT Capital Holdings	3.3x	0.3x	19.77%	★★★★☆☆
China XLX Fertiliser	12.2x	0.4x	43.38%	★★★☆☆☆
SiteMinder	NA	3.7x	37.81%	★★★☆☆☆
BCI Minerals	NA	326.7x	17.61%	★★★☆☆☆

Click here to see the full list of 55 stocks from our Undervalued Asian Small Caps With Insider Buying screener.

Here we highlight a subset of our preferred stocks from the screener.

DMCI Holdings (PSE:DMC)

Simply Wall St Value Rating: ★★★★☆☆

Overview: DMCI Holdings is a diversified company primarily engaged in construction, nickel mining, and other related activities, with a market capitalization of ₱107.89 billion.

Operations: The primary revenue streams are from construction and other activities, with significant contributions from nickel mining. The company's cost of goods sold (COGS) has been a substantial part of its expenses, impacting the gross profit margin which peaked at 51.49% in September 2022 before declining to 30.71% by March 2026. Operating expenses include general and administrative costs, with notable fluctuations over time affecting net income margins.

PE: 6.6x

DMCI Holdings, a small player in the Asian market, recently saw insider confidence with Maria Cristina Gotianun purchasing 1.2 million shares valued at approximately PHP 11.64 million between April and May 2026. Despite a slight decline in Q1 earnings to PHP 4,868.82 million from last year's PHP 5,108.85 million, the company maintains potential due to its strategic focus on external borrowing for funding. However, dividend decreases could signal caution for investors evaluating future growth prospects.

• Take a closer look at DMCI Holdings' potential here in our valuation report.

• Evaluate DMCI Holdings' historical performance by accessing our past performance report.

East West Banking (PSE:EW)

Simply Wall St Value Rating: ★★★★★☆

Overview: East West Banking is a financial institution offering retail, consumer, and corporate banking services, along with treasury and trust operations, with a market capitalization of approximately ₱43.53 billion.

Operations: East West Banking generates revenue primarily from Consumer Banking and Retail Banking, with significant contributions also coming from Corporate Banking and Treasury and Trust services. The company's net income margin has shown varied trends, reaching 25.16% in early 2026. Operating expenses are a major component of costs, with General & Administrative Expenses being substantial within this category.

PE: 2.9x

East West Banking, a smaller player in Asia's financial sector, presents an intriguing opportunity for value-seeking investors. With insider confidence evident from Jonathan Gotianun's purchase of 397,900 shares valued at ₱4.84 million between May and June 2026, the bank signals potential growth despite challenges like a high bad loans ratio of 4.3% and low allowance for bad loans at 76%. Earnings are forecast to grow by nearly 9% annually. Recent leadership changes aim to bolster compliance and credit management frameworks, potentially enhancing operational stability and governance.

• Click here to discover the nuances of East West Banking with our detailed analytical valuation report.

• Gain insights into East West Banking's past trends and performance with our Past report.

Raffles Medical Group (SGX:BSL)

Simply Wall St Value Rating: ★★★☆☆☆

Overview: Raffles Medical Group operates a network of hospitals, insurance services, and healthcare facilities with a market cap of approximately SGD 2.1 billion.

Operations: The company generates revenue from four main segments: Hospital Services, Insurance Services, Healthcare Services, and Investment Holdings. Over recent periods, the gross profit margin has shown a notable increase to 55.07% as of June 2023. Operating expenses and non-operating expenses are significant cost components impacting net income.

PE: 24.3x

Raffles Medical Group, a healthcare provider in Asia, recently reported a dip in half-year sales to S$353.19 million from S$378.45 million the previous year, with net income also slightly down. Despite this, insider confidence is evident as executives have shown interest through share purchases earlier this year. The company anticipates continued profitability for 2026 and has increased its dividend to 3 Singapore cents per share for FY2025. Recent board changes and new auditors could steer fresh strategic directions amidst their reliance on external funding sources.

• Click here and access our complete valuation analysis report to understand the dynamics of Raffles Medical Group.

• Assess Raffles Medical Group's past performance with our detailed historical performance reports.

Seize The Opportunity

• Investigate our full lineup of 55 Undervalued Asian Small Caps With Insider Buying right here.
• Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up.
• Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free.

Searching for a Fresh Perspective?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com